IDEXX Laboratories Inc
$ 562.16
-0.46%
05 Jun - close price
- Market Cap 44,548,383,000 USD
- Current Price $ 562.16
- High / Low $ 569.06 / 560.38
- Stock P/E 41.49
- Book Value 19.64
- EPS 13.61
- Next Earning Report 2026-08-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.26 %
- ROE 0.73 %
- 52 Week High 769.98
- 52 Week Low 506.91
About
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Analyst Target Price
$709.14
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-02 | 2025-11-03 | 2025-08-04 | 2025-05-01 | 2025-02-03 | 2024-10-31 | 2024-08-06 | 2024-05-01 | 2024-02-05 | 2023-11-01 | 2023-08-01 |
| Reported EPS | 3.47 | 3.08 | 3.4 | 3.63 | 2.96 | 2.62 | 2.8 | 3.02 | 2.81 | 2.32 | 2.53 | 2.67 |
| Estimated EPS | 3.41 | 2.94 | 3.15 | 3.3 | 2.85 | 2.4 | 2.69 | 2.87 | 2.67 | 2.12 | 2.37 | 2.47 |
| Surprise | 0.06 | 0.14 | 0.25 | 0.33 | 0.11 | 0.22 | 0.11 | 0.15 | 0.14 | 0.2 | 0.16 | 0.2 |
| Surprise Percentage | 1.7595% | 4.7619% | 7.9365% | 10% | 3.8596% | 9.1667% | 4.0892% | 5.2265% | 5.2434% | 9.434% | 6.7511% | 8.0972% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 3.94 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IDXX
2026-06-03 16:53:00
IDEXX Laboratories Inc. (IDXX) shares advanced 1.80% to $560.73 on Wednesday, outperforming the S&P 500 Index and Dow Jones Industrial Average, which both saw declines. Despite the strong trading day for IDEXX, the company's stock closed 27.18% below its 52-week high.
2026-06-02 20:59:45
IDEXX Laboratories' Executive Vice President George Fennell reported the vesting of restricted stock units (RSUs) on June 1, 2026. He acquired 639 shares of common stock from these units, while 284 shares were withheld to cover tax obligations. Following these transactions, Fennell's direct holdings increased to 10,433 shares of IDEXX common stock.
2026-06-02 16:51:00
IDEXX Laboratories Inc. (IDXX) stock slid 2.82% on Tuesday, closing at $550.82, despite a positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains. IDEXX stock is currently trading 28.46% below its 52-week high reached on November 26th.
2026-06-02 10:07:15
Boston Scientific (BSX) stock has experienced a significant downturn, losing 17% over a five-day losing streak, wiping out $15 billion from its market cap. Despite this decline, the article suggests the stock is "Attractive" due to strong operating performance and financial health, with a "Moderate valuation." It also highlights Trefis's High Quality Portfolio's ability to manage stock-specific risks and historical performance against the S&P 500.
2026-06-01 10:18:00
IDEXX Laboratories recently expanded its Fecal Dx antigen testing and integrated the SDMA kidney biomarker into Catalyst CLIPs, aiming to deepen its role in early disease detection and potentially increase reliance on its diagnostic platforms. This move supports IDEXX's investment narrative of recurring revenue through expanded test menus, especially if SDMA integration encourages routine use without extra cost. While these upgrades are directionally positive, investors should still consider potential impacts from softer clinic traffic and pricing pressures, which could affect the company's projected revenue and earnings growth.
2026-06-01 10:13:00
IDEXX Laboratories (IDXX) is a significant player in the diagnostics and research industry with a market cap of $44.45 billion. Analysts project a potential upside of 25.84%, with an average target price of $709.14, despite the stock currently trading below its 50-day and 200-day moving averages. The company shows strong financial performance with 14.30% revenue growth and 72.92% return on equity, and a favorable analyst rating of 9 buy, 5 hold, and 1 sell.
